



Self-forming in vivo dosimeter for radiation therapy verification

Inventors:

Sebastián L. Vega, Assistant Prof. Biomedical Engineering, Rowan University
Kirstene Gultian, Research Assistant, Biomedical Engineering, Rowan University
Leonard Kim, Chief Medical Physicist, MD Anderson Cancer Center at Cooper
Irina Malajovich, Medical Physicist, MD Anderson Cancer Center at Cooper
Geoffrey Ibbott, Professor Emeritus, Radiation Physics, UT MD Anderson Cancer Center

Brief Description:

An injectable dosimeter for real-time, in-vivo verification of MR-guided radiation therapy (MRgRT)

Problem:

Radiation therapy (RT) is one of the most common treatment modalities for cancer and is used in ~ 50% of all treatment plans. Approximately 30% of all cancer survivors in the USA receive RT, projected to reach 4.17 million by 2030. Although RT effectively kills cancer, it can cause damage to healthy tissues with significant treatment-related morbidity. Hence, it's vital to verify and monitor the radiation dose to the tumor and protect the adjacent healthy tissues from acute and long-term side effects.

Solution:

The inventors have developed an injectable, in-vivo dosimetry system for use in MRgRT based on Fricke dosimetry and a self-forming hydrogel system using norbornene-tetrazine click chemistry.

Competitive Advantages

- A novel injectable, MR-readable dosimeter, suitable for real-time in-vivo MRgRT dosimetry at clinically-relevant dose levels (2-100 Gy) for multiple irradiations over several weeks
- Can be used to improve dose uniformity (bolus) and reduce exposure to normal tissues (spacer).

Opportunity

- \$7 billion global radiation oncology market in 2020 with expected 7.3% growth pa to 2027
- \$774 million medical dosimeters market in 2017 with expected 7.1% growth pa to 2022

Stage of Development

Proof of concept – porcine tissue phantom. The system has been characterized under conditions relevant to in-vivo dosimetry: MRI dose response at body temperature over multiple irradiation sessions with variable injection-to-irradiation time intervals.

Partnerships

Co-Development, Licensing

Intellectual Property

US Provisional Patent Application

Contact

Neal Lemon, PhD, MBA Director, Cooper Innovation Center lemon-neal@cooperheatlh.edu





Figure 1 shows T1-weighted image intensity values of the dosimeter at body temperature as a function of cumulative radiation dose over five weekly fractions (Fx). The signal returns to baseline between fractions, allowing for re-use during fractionated delivery.



Figure 2 shows pre- and post-irradiation images of an injected pork phantom with annotation showing the image intensity change. The images show the dosimeter well-localized and showing signal change after irradiation. This is further highlighted in the difference image (Figure 2D).



Cooper Innovation Center | 101 Haddon Aven, Suite 402 | Camden, NJ, 08103